THZ1 Dihydrochloride

• CAT Number: L015923
• CAS Number: 2095433-94-4
• Molecular Formula: C31H30Cl3N7O2
• Molecular Weight: 639.00
• Purity: ≥95%
• Storage: 2-8°C
• IUPAC Name: N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide;dihydrochloride
• InChI: InChI=1S/C31H28ClN7O2.2ClH/c1-39(2)16-6-11-28(40)35-21-14-12-20(13-15-21)30(41)36-22-7-5-8-23(17-22)37-31-34-19-26(32)29(38-31)25-18-33-27-10-4-3-9-24(25)27;;/h3-15,17-19,33H,16H2,1-2H3,(H,35,40)(H,36,41)(H,34,37,38);2*1H/b11-6+
• InChIKey: AJTGQOACYBCREM-QVLKBJGCSA-N
• SMILES: CN(C)C/C=C/C(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl.Cl.Cl

THZ1 dihydrochloride（Cat No.:L015923）is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), a key regulator in the transcriptional and cell cycle control processes. By inhibiting CDK7, THZ1 disrupts the phosphorylation of RNA polymerase II, leading to reduced expression of oncogenes and promoting apoptosis in cancer cells. This compound has shown promise in preclinical studies for various malignancies, including leukemia and solid tumors. Its ability to target CDK7’s role in both transcription and cell cycle regulation makes THZ1 a potential therapeutic agent in cancer treatment, particularly in combination with other therapies.